title: Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010.
abstract: OBJECTIVE
  To examine temporal trends in plasma viral load (pVL) suppression and antiretroviral resistance from 1997 to 2010 in British Columbia (BC), Canada, and determine characteristics, pVL ranges, and resistance profiles of HIV-positive individuals with unsuppressed pVL in 2010.
  
  
  METHODS
  HIV-positive individuals ≥19 years old in the provincial database at the BC Centre for Excellence in HIV/AIDS were included. Virological suppression was defined as 2 consecutive pVL <500 copies per milliliter within each calendar year. Temporal trends were evaluated using the Cochran-Armitage test. Persons with suppressed vs. unsuppressed pVL in 2010 were compared using the Pearson χ² or Fisher exact test (categorical variables) and the Wilcoxon rank-sum test (quantitative variables), including unsuppressed individuals only if they were on antiretroviral therapy (ART) in 2010 or their baseline CD4 count was <350 cells per cubic millimeter or <500 cells per cubic millimeter, in separate analyses.
  
  
  RESULTS
  The proportion of individuals with suppressed pVL increased from 24% to 80% (P < 0.001). In comparative analyses, individuals with unsuppressed pVL (877 of 6142) were more likely to be female (30% vs. 16%), younger (median, 43 vs. 48 years), have injection drug use history (38% vs. 30%), report Aboriginal ancestry (30% vs. 16%), and have hepatitis C coinfection (57% vs. 34%) (all P < 0.001). Similar patterns were observed using the <500 cells per cubic millimeter CD4 cutoff. The median pVL of all unsuppressed individuals in 2010 was 12,896 copies per milliliter (interquartile range, 1495-47,763).
  
  
  CONCLUSIONS
  The proportion of individuals achieving pVL suppression in BC has increased markedly since 1997; however, further efforts are needed to maximize the individual and societal benefits of modern antiretroviral therapy.
authors: *British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; †University of British Columbia, Vancouver, British Columbia, Canada; and ‡Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
authors: Angela
authors: A
authors: Cescon
authors: Steve
authors: S
authors: Kanters
authors: Chanson J
authors: CJ
authors: Brumme
authors: Katherine J
authors: KJ
authors: Lepik
authors: Jamie I
authors: JI
authors: Forrest
authors: Mark
authors: M
authors: Hull
authors: Hasina
authors: H
authors: Samji
authors: Bohdan
authors: B
authors: Nosyk
authors: P Richard
authors: PR
authors: Harrigan
authors: Robert S
authors: RS
authors: Hogg
authors: Julio S G
authors: JS
authors: Montaner
mesh_terms: D000328:Adult; D000367:Age Factors; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001955:British Columbia / Q000453:epidemiology; D024882:Drug Resistance, Viral; D005260:Female; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors; D012737:Sex Factors; D019562:Viral Load / Q000187:drug effects / Q000706:statistics & numerical data
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral
references: Lancet. 1997 May 3;349(9061):1294
references: 9142067
references: J Clin Virol. 2007 Apr;38(4):304-12
references: 17329164
references: Lancet. 2010 Aug 14;376(9740):532-9
references: 20638713
references: AIDS Behav. 2011 Nov;15(8):1612-22
references: 21850442
references: HIV Med. 2011 Jul;12(6):352-60
references: 21059167
references: J Infect Dis. 2004 Sep 1;190(5):879-85
references: 15295691
references: JAMA. 1998 Feb 11;279(6):450-4
references: 9466638
references: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):500-5
references: 18197117
references: J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):275-83
references: 11873077
references: Lancet. 2006 Mar 11;367(9513):817-24
references: 16530575
references: AIDS. 2007 Mar 30;21(6):685-92
references: 17413689
references: Clin Infect Dis. 2011 Mar 15;52(6):793-800
references: 21367734
references: J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):393-9
references: 22134149
references: AIDS. 2009 Jul 17;23(11):1397-404
references: 19381076
references: Harm Reduct J. 2006 Dec 18;3:36
references: 17176481
references: Curr Opin HIV AIDS. 2009 May;4(3):194-9
references: 19532050
references: PLoS One. 2010 Jun 10;5(6):e11068
references: 20548786
references: BMJ. 2009 Apr 30;338:b1649
references: 19406887
references: AIDS Care. 2009 May;21(5):638-44
references: 19444673
references: AIDS. 2008 Oct 18;22(16):2179-85
references: 18832881
references: Lancet. 2010 Jun 12;375(9731):2092-8
references: 20537376
references: JAMA. 1996 Jul 10;276(2):146-54
references: 8656507
references: JAMA. 2012 Jul 25;308(4):387-402
references: 22820792
references: JAMA. 2010 Jul 21;304(3):321-33
references: 20639566
references: Drug Alcohol Rev. 2009 Jul;28(4):341-6
references: 19594786
references: N Engl J Med. 2011 Aug 11;365(6):493-505
references: 21767103
references: Lancet. 2006 Aug 5;368(9534):531-6
references: 16890841
references: N Engl J Med. 2000 Mar 30;342(13):921-9
references: 10738050
references: Addiction. 2010 May;105(5):907-13
references: 20331553
references: Int J Drug Policy. 2007 Aug;18(4):281-7
references: 17689376
references: Top Antivir Med. 2011 Nov;19(4):156-64
references: 22156218
references: AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):901-10
references: 11461676